Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SV and Polaris Back Gerngross' New Antibody Play

This article was originally published in Start Up

Executive Summary

Adimab is the latest venture in the resurgent large-molecule platform space. The company is founded by yeast platform pioneers Tillman Gerngross (Glycofi, Dartmouth) and Dane Wittrup (BioDisplay, MIT). The company's Series A pulled in $6.2 million from lead backers SV Life Sciences and Polaris Venture Partners.

You may also be interested in...



Adimab Inks Merck, Roche Deals and Banks on the Value of Discovery

Adimab, the yeast-based antibody discovery biotech, has signed its first two alliances. In doing so the company revealed to Start-Up its partnering strategy, and discussed why it won't take a single step down the value chain into drug development. Can Adimab make discovery-only work where others have failed?

Postcards from BIO: Observations on Start-Up Financing and Dealmaking

This year's annual Biotechnology Industry Organization was chock-full of angst, with biotech clearly in a contraction amid bankruptcies, scarce financing, and few exits in sight. START-UP was there to chronicle some of the technological and financial highlights, to gauge the pulse of industry, and to talk to a variety of biotech and pharmaceutical executives about the future of biotech dealmaking. Snapshots here include the unveiling of Adimab's platform, the NIH's new bridge funding option; and a positive message on anti-infectives development . More of our BIO coverage can be found on The IN VIVO Blog (http://invivoblog.blogspot.com).

Postcards from BIO: Observations on Start-Up Financing and Dealmaking

This year's annual Biotechnology Industry Organization was chock-full of angst, with biotech clearly in a contraction amid bankruptcies, scarce financing, and few exits in sight. START-UP was there to chronicle some of the technological and financial highlights, to gauge the pulse of industry, and to talk to a variety of biotech and pharmaceutical executives about the future of biotech dealmaking. Snapshots here include the unveiling of Adimab's platform, the NIH's new bridge funding option; and a positive message on anti-infectives development . More of our BIO coverage can be found on The IN VIVO Blog (http://invivoblog.blogspot.com).

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1122113

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel